(614)355-5560
South Central / Southeast Region
October 13, 2021
Behavioral Health Red Flag Series: Antipsychotic Medications

It is important for providers to be aware of “red flag” symptoms associated with adverse events of medications and to use office visits as opportunities to identify potentially severe medication side effects, even if the visit is not medication focused. Within this article, the third in the series, we will cover Antipsychotic medication “red flags”.

Medication: Antipsychotics (Aripiprazole, Risperidone, Lurasidone, Quetiapine)

Concern: Metabolic abnormalities, Extrapyramidal (movement) disorders, and Neuroleptic Malignant Syndrome

Monitoring: Blood glucose/A1C, Lipid labs/LDL-C labs, and Abnormal Involuntary Movement Scale (AIMS)

Refer to the following link for Lab monitoring assistance and schedule: W248303-PFK_APM-Lab-Monitoring-Tool_2020.pdf (partnersforkids.org)

Refer to the following link for the AIMS form: ABNORMAL INVOLUNTARY MOVEMENT SCALE (AIMS) (aacap.org)

Instructions for a physical exam to assist with completion of AIMS be found here: tool_aims.pdf (cqaimh.org)

Considerations before beginning antipsychotic medications or increasing the doses:

  • Review full medical history, especially those related to the “red flags” and the other considerations below.
  • Cardiac history: Antipsychotics may increase risk of QTc prolongation, with the risk being greater in those with preexisting cardiac concerns.
  • History of seizure or epilepsy: Antipsychotics may lower the seizure threshold. Providers may utilize BH-TIPS for assistance with medication selection.
  • Behavioral Health Treatment Insights and Provider Support (BH-TIPS) (nationwidechildrens.org)

RED FLAG Presentation: Differs depending on affected system, see chart below

*Due to interpatient variability among pediatrics, medication selection will be patient-specific. If concerned, utilize Behavioral Health or Neurology consultation to guide treatment.
For assistance with management of Metabolic dysfunction and Extrapyramidal symptoms, a Nationwide Children’s Hospital psychiatrist may be consulted via private Zoom conference. Schedule a meeting here: Behavioral Health Treatment Insights and Provider Support (BH-TIPS) (nationwidechildrens.org)

Published October 2021

Risk Presentation Actions
Metabolic dysfunction
  • Elevated Glucose/HbA1C, possible overt Diabetes
  • Elevated Lipids/ LDL-C, possible overt Hyperlipidemia
  • Increased BMI
  • Consider dose reduction or switch to a medication with less risk of metabolic disturbance
  • Encourage healthy eating habits and routines when applicable
  • Consult Endocrinology
Extrapyramidal (Movement) disorders Acute symptoms, may occur within days of initiating of an antipsychotic:

  • Muscle spasms of the face, back and extremities that may be painful
  • Abnormal posture
  • Akathisia – a sense of restlessness and inability to stay still
  • Often distressing to a patient

Delayed Symptoms, typically occur months to years after initiation of an antipsychotic:

  • Involuntary painless movements of face and limbs
  • Puckering or smacking lips, tongue rolling and moving in and out of the mouth
  • Abnormal posture
  • Instability while walking, or abnormal gait
  • Akathisia – a sense of restlessness and inability to stay still
  • May become permanent if not addressed

 

Mild or minimally bothersome to patient:

  •  If not already using AIMS to track movements, initiate AIMS monitoring and record changes
  • If worsening symptoms, reduce dose

Moderate-Severe and/or bothersome to patient:

  • Reduce dose, discontinue medication or select an agent with less risk of movement symptoms
  • When dose reduction is not feasible, consider addition of a medication for symptom control*
  • Refer to behavioral health specialist
Neuroleptic Malignant Syndrome Acute symptoms, usually within 2 weeks after initiation or dose increase of an antipsychotic. Higher risks with higher doses and drug-drug interactions:

  • High fever
  • Sweating
  • Unstable blood pressure
  • Impacted cognition – disorientation, dizziness, “brain fog”
  • Muscle rigidity
  • Discontinue medication immediately
  • Refer to emergency care
Related Articles
Pharmacy Updates
October 6, 2022
Quarter 4 Partners For Kids Unified Preferred Drug List Now Available
Read More
Pharmacy Updates
October 6, 2022
RSV Season – Medicaid Plans Now Covering Palivizumab (Synagis®) for Qualifying Patients
Read More
Pharmacy Updates
August 18, 2022
UPDATED: Format and Content for Partners For Kids Asthma Prescribing Resource
Review the updated “Prescribing Guidelines for Asthma” that include a new pathway to assist with decision-making, clickable elements to assist navigation throughout the resource and more.
Read More
Pharmacy Updates
June 16, 2022
Flovent HFA Inhaler Now Has a Generic; Brand Still Preferred for Medicaid Patients
Learn how to ensure your patients continue to receive the brand name medication.
Read More
Pharmacy Updates
June 16, 2022
RSV Season May Start Early Again This Year
Read about the indicators suggesting an early RSV season and planned communication to providers regarding Synagis administration. Learn about RSV resources for your providers and patients.
Read More
Pharmacy Updates
June 3, 2022
Resources for Early RSV Season
Read More